229 alliance deals were signed in the pain management sector between 2012 and November 2016, worth more than $1bn in upfront payments and around $11bn in total potential value. But an increase in deals for riskier, earlier stage assets has pushed down upfront payment values for the sector, knocking it out of sync with other therapy areas.
Surprisingly, companies developing pain therapeutics – a well-served market – are also some of the most prolific researchers, with more than 341 Phase I to Phase III/IV active clinical trials as of November 2016. The sector has also signed 229 pain management-focused deals over the last five years, worth a combined $11bn in total potential value.
This value ranks pain partnerships as some of the most lucrative within the CNS field, according to data from Informa...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
